Novartis's up-to-$3.2 billion licensing deal for Alteogen's ALT-B4 hyaluronidase enzyme is the fourth subcutaneous-conversion ...

The FDA approves zilganersen, the first disease-modifying Alexander disease therapy, offering rare disease developers a trial ...

Tara Dougal, event director for pharma at Informa Markets and head of CPHI Milan, previews the 2026 show in an interview with ...

On August 31, 2026, Eli Lilly announced it has entered a definitive agreement to acquire Merida Biosciences, a biotechnology ...

Novartis obtained portfolio-level options for exclusive rights to Hybrozyme-enabled SC formulations, with economics up to ...

Extending CAR T beyond cancer alters risk–benefit calculus, because chronic autoimmune populations have alternative therapies ...

Marco Anelli, MD | Authors | Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and expert industry news.

David S. Thompson, CSAP, is Chief Alliance Officer at Eli Lilly and Company.

In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor. PhD, AbbVie, and Swita Singh, PhD, Bristol ...

The FDA cleared four notable therapies within the same week in late August, spanning infectious disease, cardiometabolic care ...

FDA approves Rasonque (daraxonrasib), the first broad RAS-targeted therapy for metastatic pancreatic cancer, validating RAS ...

In December 2025, FDA announced that it was deploying agentic AI capabilities across the agency. FDA defined these systems as ...